{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-049931","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2024-12-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.210315+00:00","generated_at":"2026-05-29T08:23:25.791321+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"InfuSystem provides 2024 guidance: revenue ~$134.2M, adjusted EBITDA ~$26.5M","bullets":["TTM revenue through 9/30/24 $132.8M; estimated FY2024 revenue $134.2M (high single-digit growth).","Adjusted EBITDA estimated at $26.5M for FY2024, margin ~19.7% (high teens % of revenue).","Net leverage ratio 1.15x; debt/equity 0.90x; $20M stock repurchase program available.","Capital allocation prioritized: organic growth, debt reduction (target leverage 1.5x-2.0x), and opportunistic buybacks.","Patient Services gross margin improved to 66.0% TTM; Device Solutions gross margin 31.3% TTM."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-049931","json":"https://secwatch.observer/filing/0001628280-24-049931.json","markdown":"https://secwatch.observer/filing/0001628280-24-049931.md","text":"https://secwatch.observer/filing/0001628280-24-049931.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/0001628280-24-049931-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828024049931/infu-20241204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T08:23:25.791321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}